CompletedPhase 2NCT00003151
Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma
Studying MALT lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Principal Investigator
- Patrice P. Carde, MDGustave Roussy, Cancer Campus, Grand Paris
- Intervention
- bismuth subcitrate(dietary_supplement)
- Enrollment
- 96 target
- Eligibility
- 18 years · All sexes
- Timeline
- 1997
Study locations (22)
- Royal United Hospital, Bath, England, United Kingdom
- University Birmingham N.H.S. Trust, Birmingham, England, United Kingdom
- Royal Free Hospital, Hampstead, London, England, United Kingdom
- St. James's Hospital, Leeds, England, United Kingdom
- Saint Bartholomew's Hospital, London, England, United Kingdom
- Royal Free Hospital School of Medicine, London, England, United Kingdom
- Guy's, King's and St. Thomas' Hospitals Trust, London, England, United Kingdom
- Royal Marsden NHS Trust, London, England, United Kingdom
- Hammersmith Hospital, London, England, United Kingdom
- Middlesex Hospital- Meyerstein Institute, London, England, United Kingdom
- Charing Cross Hospital, London, England, United Kingdom
- Clatterbridge Centre for Oncology NHS Trust, Merseyside, England, United Kingdom
- Newcastle General Hospital, Newcastle upon Tyne, England, United Kingdom
- Mount Vernon Hospital, Northwood, England, United Kingdom
- Nottingham City Hospital NHS Trust, Nottingham, England, United Kingdom
- +7 more locations on ClinicalTrials.gov
Collaborators
University of Glasgow
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00003151 on ClinicalTrials.govOther trials for MALT lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06510309Rituximab Plus Venetoclax in Front Line Marginal Zone LymphomaGottfried von Keudell, MD PhD
- RECRUITINGPHASE2NCT07441993Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZLInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07372365Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.The First Affiliated Hospital of Soochow University
- RECRUITINGPHASE2NCT06796998Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)Izidore Lossos, MD
- RECRUITINGNCT06712459Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone LymphomaInternational Extranodal Lymphoma Study Group (IELSG)
- ACTIVE NOT RECRUITINGPHASE2NCT07480863Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZLCancer Institute and Hospital, Chinese Academy of Medical Sciences
- ACTIVE NOT RECRUITINGPHASE2NCT07247383Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT LymphomaSecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGPHASE2NCT07208981Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZLThe First Affiliated Hospital with Nanjing Medical University